Notch Therapeutics

Notch Therapeutics has developed a universal T cell derived from a renewable cell source: induced pluripotent stem cells (iPSCs). Notch’s UNi-T Cell is an off-the-shelf solution that removes the need for the modification and manufacture of patient-specific cells and signals the dawn of a new era in CAR-T therapies.

Persistent and potent cell therapies, with patient experience and access in mind.

Notch’s end-to-end capabilities in iPSC-T therapeutics development recognize and respond to the unique challenges posed by using living cells. Our UNi-T Cell product, proprietary manufacturing process, and internal product pipeline have been designed to improve on the clinical success of CAR-Ts while simultaneously tackling the associated commercial and economic challenges.

Achieving durable and robust tumour control.

We continue to develop an internal pipeline of therapies. In recent in vivo testing, our CD19 CAR UNi-T Cells eliminated tumors within the first week of study and maintained complete tumor remission. The CD19 CAR product targets and kills tumor cells, safely expands in response to malignant cells and traffics to the site of the disease. We have also developed novel and potent approaches to protect UNi-T Cells from a patient’s immune system and eliminate the need for lymphodepleting chemotherapy.

Notch’s iPSC engineering platform generates uniformly engineered cell therapies. Drug potency is the same, no matter the cell batch, meaning every treatment a patient receives is as potent as the previous one – something that isn’t the case with current autologous therapies. The platform also mitigates safety and supply chain issues from viral vectors, while enabling sophisticated product designs to address multiple disease mechanisms.

Delivering affordability and accessibility to the clinic.

To maximize their benefits to patients, cell therapies need to be available to people at the time of diagnosis. These products need to be shelf-stable, standardized, and affordable. Scalability drives cost, and Notch’s proprietary manufacturing process—which includes our regulatory-compliant, small-footprint bioreactor technology—enables unprecedented scale while delivering low variability in the products patients receive. The result? Our UNi-T Cells significantly reduce the cost per dose of CAR-T therapy by more than 100 times the cost of current alternatives, making it possible to enhance treatment outcomes for more patients than ever before.

Making cell therapies more drug-like.

Notch’s universal, allogeneic chassis line enables multiple product candidates and partnering opportunities. The focus of our internal pipeline is on finding ways to serve large numbers of patients with safe and effective therapies. Our CD19 + CD20 CAR UNi-T product for B-cell non-Hodgkin lymphoma and autoimmune indications is at the Preclinical / Proof of Concept stage, with two more oncology products in Discovery, including our DLL3 CAR product for small-cell lung cancer. Notch continues to work with partner, Allogene, to advance development of another oncology product, and is well suited to support additional partnering opportunities as they arise.

Facilitating market expansion and the success of CAR-T therapies.

Founded in 2018, with sites in Toronto, Vancouver, and Seattle, our team of Notchos comprises some of the most brilliant minds in preclinical science, advanced cell manufacturing, bioengineering, and systems biology. Internally and with partners, we are working to maximize the benefits and reach of new generations of cellular immunotherapies.